Biotech Stock Performance Review -- NewLink Genetics, Ocera Therapeutics, Ocular Therapeutix, and Omeros

Tuesday, July 11, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, July 11, 2017 /PRNewswire/ --

If you want a Stock Review on NLNK, OCRX, OCUL or OMER then come over to and sign up for your free customized report today. Today's research on draws investors' attention to NewLink Genetics Corp. (NASDAQ: NLNK), Ocera Therapeutics Inc. (NASDAQ: OCRX), Ocular
Therapeutix Inc. (NASDAQ: OCUL), and Omeros Corp. (NASDAQ: OMER). On July 02nd, 2017, Oppenheimer's analyst said in a research note that the investment firm is starting to see an increase in expectations for the Biotech sector, with anticipated 2018 earnings growth increasing to 6.4% in June from 6.1% in May, and with expectations for S&P 500 earnings growth unchanged at 11.6%. These free stocks reports are currently available on Simply sign up for your complimentary member access at:

NewLink Genetics 

Ames, Iowa headquartered NewLink Genetics Corp.'s stock finished Monday's session 0.78% lower at $7.63. A total volume of 996,078 shares was traded, which was above their three months average volume of 936,800 shares. Over the last month, the Company's shares have advanced 22.28%. The stock is trading below its 50-day moving average by 35.79%. Moreover, shares of NewLink Genetics, which focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer, have a Relative Strength Index (RSI) of 33.55.

On July 07th, 2017, NewLink Genetics announced that it will release its Q2 2017 financial results on July 28th, 2017. The Company has scheduled a conference call for 8:30 a.m. ET on the same day to discuss the results and to give an update on its clinical and development activities. The conference call will be webcast live, and a link can be accessed via the Company's website. Your complete research report on NLNK can be retrieved for free at:

Ocera Therapeutics 

Shares in Palo Alto, California headquartered Ocera Therapeutics Inc. jumped 5.26%, ending yesterday's session at $1.20. A total volume of 780,120 shares was traded, which was above their three months average volume of 473,190 shares. The stock has gained 20.00% in the past month. The Company's shares are trading 6.93% above their 50-day moving average. Moreover, shares of Ocera Therapeutics, which operates as a clinical stage biopharmaceutical company, have an RSI of 64.81. A free report on OCRX is just a click away at:

Ocular Therapeutix 

On Monday, Bedford, Massachusetts headquartered Ocular Therapeutix Inc.'s stock saw a drop of 8.85%, to close the day at $6.49. A total volume of 4.60 million shares was traded, which was above their three months average volume of 1.03 million shares. The Company's shares are trading 23.96% below their 200-day moving average. Additionally, shares of Ocular Therapeutix, which focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the US, have an RSI of 27.17.  

On June 22nd, 2017, Ocular Therapeutix announced that Antony Mattessich will succeed Dr. Amar Sawhney as CEO on or before September 30th, 2017. Mr. Mattessich has also been elected to the Company's Board of Directors, effective immediately. Meanwhile, Dr. Sawhney will continue to serve as CEO and Chairman of the Board of Directors, and will then transition to an Executive Chairman role. As Executive Chairman, Dr. Sawhney will continue to devote substantial business time to the Company.

On June 23rd, 2017, research firm Morgan Stanley downgraded the Company's stock rating from 'Overweight' to 'Equal-Weight'. Sign up for your complimentary research report on OCUL at:


Shares in Seattle, Washington-based Omeros Corp. ended the day 7.54% higher at $20.55. A total volume of 1.06 million shares was traded, which was above their three months average volume of 982,420 shares. The stock has surged 37.00% in the last one month, 24.70% in the previous three months, and 107.16% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 13.51% and 58.59%, respectively. Furthermore, shares of Omeros, which discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system, have an RSI of 51.19.  

On June 29th, 2017, Omeros stated that it is aware of a report posted online by a certain "Art Doyle," an entity or group that appears to be concealing its identity and is purportedly writing on behalf of itself or one or more employers. The report is replete with falsehoods, misleading statements, and incorrect analyses and conclusions. The Company is pursuing legal remedies and intends to hold all responsible parties accountable. Register for free on and download the latest research report on OMER at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store